Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

This study has been completed.
Information provided by (Responsible Party):
Pharmacyclics Identifier:
First received: February 2, 2011
Last updated: March 30, 2016
Last verified: March 2016